Next Article in Journal
Novel Strategies for Cancer Treatment: Highlights from the 55th IACR Annual Conference
Next Article in Special Issue
Do GNAQ and GNA11 Differentially Affect Inflammation and HLA Expression in Uveal Melanoma?
Previous Article in Journal
The Histone Demethylase Enzymes KDM3A and KDM4B Co-Operatively Regulate Chromatin Transactions of the Estrogen Receptor in Breast Cancer
Previous Article in Special Issue
Families with BAP1-Tumor Predisposition Syndrome in The Netherlands: Path to Identification and a Proposal for Genetic Screening Guidelines
Open AccessArticle

Predicting Visual Acuity Deterioration and Radiation-Induced Toxicities after Brachytherapy for Choroidal Melanomas

1
Department of Oncology, Section of Radiotherapy, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark
2
Department of Ophthalmology, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark
3
Leeds Institute of Medical Research at St James’s, University of Leeds, Leeds LS9 7TF, UK
4
Department of Physical Sciences, The Peter MacCallum Cancer Centre, Melbourne 3000, Australia
5
Department of Radiation Oncology, Centre Francois Baclesse, 14000 Caen, France
6
Laboratoire de Physique Corpusculaire IN2P3/ENSICAEN, 14000 Caen, France
7
Laboratoire de Physique Corpusculaire IN2P3/ENSICAEN-UMR6534, Unicaen–Normandy University, 14000 Caen, France
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(8), 1124; https://doi.org/10.3390/cancers11081124
Received: 28 June 2019 / Revised: 23 July 2019 / Accepted: 29 July 2019 / Published: 6 August 2019
(This article belongs to the Special Issue Uveal Melanoma)
  |  
PDF [1094 KB, uploaded 6 August 2019]
  |     |  

Abstract

Ruthenium-106 (Ru-106) brachytherapy is an established modality for eye-preserving treatment of choroidal melanoma. To achieve optimal treatment outcomes, there should be a balance between tumour control and the risk of healthy tissue toxicity. In this retrospective study, we examined normal tissue complication probability (NTCP) for visual acuity deterioration and late complications to aid the understanding of dose-dependence after Ru-106 treatments. We considered consecutive patients diagnosed with choroidal melanoma and primarily treated at a single institution from 2005–2014. Treatment plans were retrospectively recreated using dedicated software and image guidance to contour the tumour and determine the actual plaque position. Dose distributions were extracted from each plan for all relevant anatomical structures. We considered visual acuity deterioration and late complications (maculopathy, optic neuropathy, ocular hypertension, vascular obliteration, cataract and retinal detachment). Lasso statistics were used to select the most important variables for each analysis. Outcomes were related to dose and clinical characteristics using multivariate Cox regressions analysis. In total, 227 patients were considered and 226 of those were eligible for analysis. Median potential follow-up time was 5.0 years (95% CI: 4.5–6.0). Visual acuity deterioration was related to optic disc-tumour distance and dose metrics from the retina and the macula, with retina V10Gy showing the strongest correlation. Macula V10Gy was the only dose metric impacting risk of maculopathy, while optic disc-tumour distance also proved important. Optic disc V50Gy had the largest impact on optic neuropathy along with optic disc-tumour distance. Optic disc V20Gy was the only variable associated with vascular obliteration. Lens D2% had the largest impact on the risk of cataract along with older age and the largest base dimension. We found no variables associated with the risk of ocular hypertension and retinal detachment. Visual acuity deterioration and most late complications demonstrated dependence on dose delivered to healthy structures in the eye after Ru-106 brachytherapy for choroidal melanomas. View Full-Text
Keywords: choroidal melanoma; brachytherapy; normal tissue complication probability; dose-response choroidal melanoma; brachytherapy; normal tissue complication probability; dose-response
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Espensen, C.A.; Appelt, A.L.; Fog, L.S.; Gothelf, A.B.; Thariat, J.; Kiilgaard, J.F. Predicting Visual Acuity Deterioration and Radiation-Induced Toxicities after Brachytherapy for Choroidal Melanomas. Cancers 2019, 11, 1124.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top